28 research outputs found
The Beta Agonist Lung Injury TrIal (BALTI) : prevention trial protocol
Background: Acute lung injury complicates approximately 25-30% of subjects undergoing oesophagectomy.
Experimental studies suggest that treatment with beta agonists may prevent the development of acute lung injury by decreasing inflammatory cell infiltration, activation and inflammatory cytokine release, enhancing basal alveolar fluid clearance and improving alveolar capillary barrier function.
Methods/Design: The Beta Agonist Lung Injury TrIal (prevention) is a multi-centre, randomised, double blind,
placebo-controlled trial. The aim of the trial is to determine in patients undergoing elective transthoracic
oesphagectomy, if treatment with inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and
continued for 72 hours thereafter compared to placebo affect the incidence of early acute lung injury and other
clinical, resource and patient focused outcomes. The primary outcome will be the development of acute lung
injury within 72 hours of oesophagectomy. The trial secondary outcomes are the development of acute lung injury during the first 28 days post operatively; PaO2: FiO2 ratio; the number of ventilator and organ failure free days, 28 and 90 day survival; health related quality of life and resource utilisation. The study aims to recruit 360 patients from 10 UK centres
Topical dermal anaesthesia inhibits the flare but not the weal response to allergen and histamine in the skin-prick test
Knowledge of Determinants of Mental Health Among Iranian Immigrants of BC, Canada: “A Qualitative Study”
Visceral angioedema: an under-recognized complication of angiotensin-converting enzyme inhibitors
Morphological and Pharmacological Evidences for the Participation of PAF-Acether in Anaphylactic Shock in the Guinea-Pig
Venous blood platelets decrease during allergen-induced asthmatic reactions.
To determine whether circulating platelets alter during asthmatic reactions induced by allergens, we studied nine subjects previously shown to develop an early or dual asthmatic reaction after inhalation challenge with extracts of house dust mite or grass pollen. In each subject, FEV1, circulating platelets and leucocytes were measured before, 15, 30 and 60 min, and 2, 4, 6 and 8 hr after inhalation of allergen and diluent control administered in a single-blind, randomized fashion. The same procedure was repeated in six of the nine subjects after bronchoconstriction induced by methacholine. Each subject developed an early asthmatic reaction after allergen inhalation challenge, which was followed by a late asthmatic reaction in six subjects and by an equivocal late asthmatic reaction in two of them (fall in FEV1 of 15 and 17% respectively). Compared with the control day, circulating platelets significantly decreased during the allergen-induced early asthmatic reaction (P less than 0.025, at 30 min). Platelet counts returned to baseline values within 4 hr and remained steady thereafter both in subjects who did and did not develop a late asthmatic reaction. No changes in platelet counts occurred after bronchoconstriction induced by methacholine. Diurnal increase of leucocyte numbers occurred after challenge with both allergen and diluent control. These results suggest that platelets may be involved in the pathogenesis of allergen-induced asthmatic reactions